NEW YORK – IncellDx and Factorial Diagnostics have inked an exclusive license and supply agreement for technology to develop their multi-omic cancer diagnostic workflow.
San Carlos, California-based Factorial will use InCellDx's new IncellMax-Seq reagent to perform in situ library preparation for next-generation sequencing (NGS) applications.
The firms believe the collaboration will allow simultaneous immunophenotyping capabilities, along with unequivocal cell pre-identification.
Factorial said its proprietary front-end technology will be compatible with multiple cell isolation methods, including fluorescence-activated and microfluidic cell-sorting.
"Current bulk, NGS-based cancer diagnostic tests are losing valuable phenotypic information during library prep," John Wells, CEO and cofounder of Factorial Diagnostics, said in a statement. "With this collaboration, Factorial aims to preserve that critical phenotypic information in order to increase clinical sensitivity and enable more precise therapeutic approaches."
Financial details of the agreement were not disclosed.
"IncellDx is continuing to advance intracellular molecular biology with its unique IncellMax-Seq reagent, which allows access to the inside of the cell while allowing simultaneous, unequivocal identification of the cell," Bruce Patterson, CEO and founder of IncellDx, said in a statement.